INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (21201, 27163, 'Radium Ra 223 dichloride', 'Liver Failure', 'No dedicated hepatic or renal impairment studies have been conducted for radium Ra 223.  Subgroup analyses in the randomized controlled trials have concluded that no dose adjustment is needed in patients with mild to moderate renal impairment, and mild hepatic impairment.  No dose adjustment can be recommended for patients with severe renal impairment or moderate to severe hepatic impairment.  Caution is advised if used in these patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (21202, 27171, 'Radium Ra 223 dichloride', 'Liver Failure', 'No dedicated hepatic or renal impairment studies have been conducted for radium Ra 223.  Subgroup analyses in the randomized controlled trials have concluded that no dose adjustment is needed in patients with mild to moderate renal impairment, and mild hepatic impairment.  No dose adjustment can be recommended for patients with severe renal impairment or moderate to severe hepatic impairment.  Caution is advised if used in these patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (21203, 27172, 'Radium Ra 223 dichloride', 'Liver Failure', 'No dedicated hepatic or renal impairment studies have been conducted for radium Ra 223.  Subgroup analyses in the randomized controlled trials have concluded that no dose adjustment is needed in patients with mild to moderate renal impairment, and mild hepatic impairment.  No dose adjustment can be recommended for patients with severe renal impairment or moderate to severe hepatic impairment.  Caution is advised if used in these patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (21204, 27173, 'Radium Ra 223 dichloride', 'Liver Failure', 'No dedicated hepatic or renal impairment studies have been conducted for radium Ra 223.  Subgroup analyses in the randomized controlled trials have concluded that no dose adjustment is needed in patients with mild to moderate renal impairment, and mild hepatic impairment.  No dose adjustment can be recommended for patients with severe renal impairment or moderate to severe hepatic impairment.  Caution is advised if used in these patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (21205, 27174, 'Radium Ra 223 dichloride', 'Liver Failure', 'No dedicated hepatic or renal impairment studies have been conducted for radium Ra 223.  Subgroup analyses in the randomized controlled trials have concluded that no dose adjustment is needed in patients with mild to moderate renal impairment, and mild hepatic impairment.  No dose adjustment can be recommended for patients with severe renal impairment or moderate to severe hepatic impairment.  Caution is advised if used in these patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (21206, 27175, 'Radium Ra 223 dichloride', 'Liver Failure', 'No dedicated hepatic or renal impairment studies have been conducted for radium Ra 223.  Subgroup analyses in the randomized controlled trials have concluded that no dose adjustment is needed in patients with mild to moderate renal impairment, and mild hepatic impairment.  No dose adjustment can be recommended for patients with severe renal impairment or moderate to severe hepatic impairment.  Caution is advised if used in these patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (21207, 27176, 'Radium Ra 223 dichloride', 'Liver Failure', 'No dedicated hepatic or renal impairment studies have been conducted for radium Ra 223.  Subgroup analyses in the randomized controlled trials have concluded that no dose adjustment is needed in patients with mild to moderate renal impairment, and mild hepatic impairment.  No dose adjustment can be recommended for patients with severe renal impairment or moderate to severe hepatic impairment.  Caution is advised if used in these patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (21208, 27177, 'Radium Ra 223 dichloride', 'Liver Failure', 'No dedicated hepatic or renal impairment studies have been conducted for radium Ra 223.  Subgroup analyses in the randomized controlled trials have concluded that no dose adjustment is needed in patients with mild to moderate renal impairment, and mild hepatic impairment.  No dose adjustment can be recommended for patients with severe renal impairment or moderate to severe hepatic impairment.  Caution is advised if used in these patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (21209, 27178, 'Radium Ra 223 dichloride', 'Liver Failure', 'No dedicated hepatic or renal impairment studies have been conducted for radium Ra 223.  Subgroup analyses in the randomized controlled trials have concluded that no dose adjustment is needed in patients with mild to moderate renal impairment, and mild hepatic impairment.  No dose adjustment can be recommended for patients with severe renal impairment or moderate to severe hepatic impairment.  Caution is advised if used in these patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (21210, 27179, 'Radium Ra 223 dichloride', 'Liver Failure', 'No dedicated hepatic or renal impairment studies have been conducted for radium Ra 223.  Subgroup analyses in the randomized controlled trials have concluded that no dose adjustment is needed in patients with mild to moderate renal impairment, and mild hepatic impairment.  No dose adjustment can be recommended for patients with severe renal impairment or moderate to severe hepatic impairment.  Caution is advised if used in these patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (21211, 27180, 'Radium Ra 223 dichloride', 'Liver Failure', 'No dedicated hepatic or renal impairment studies have been conducted for radium Ra 223.  Subgroup analyses in the randomized controlled trials have concluded that no dose adjustment is needed in patients with mild to moderate renal impairment, and mild hepatic impairment.  No dose adjustment can be recommended for patients with severe renal impairment or moderate to severe hepatic impairment.  Caution is advised if used in these patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (21212, 27182, 'Radium Ra 223 dichloride', 'Liver Failure', 'No dedicated hepatic or renal impairment studies have been conducted for radium Ra 223.  Subgroup analyses in the randomized controlled trials have concluded that no dose adjustment is needed in patients with mild to moderate renal impairment, and mild hepatic impairment.  No dose adjustment can be recommended for patients with severe renal impairment or moderate to severe hepatic impairment.  Caution is advised if used in these patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (21213, 27183, 'Radium Ra 223 dichloride', 'Liver Failure', 'No dedicated hepatic or renal impairment studies have been conducted for radium Ra 223.  Subgroup analyses in the randomized controlled trials have concluded that no dose adjustment is needed in patients with mild to moderate renal impairment, and mild hepatic impairment.  No dose adjustment can be recommended for patients with severe renal impairment or moderate to severe hepatic impairment.  Caution is advised if used in these patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (21214, 27188, 'Radium Ra 223 dichloride', 'Liver Failure', 'No dedicated hepatic or renal impairment studies have been conducted for radium Ra 223.  Subgroup analyses in the randomized controlled trials have concluded that no dose adjustment is needed in patients with mild to moderate renal impairment, and mild hepatic impairment.  No dose adjustment can be recommended for patients with severe renal impairment or moderate to severe hepatic impairment.  Caution is advised if used in these patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (21215, 27189, 'Radium Ra 223 dichloride', 'Liver Failure', 'No dedicated hepatic or renal impairment studies have been conducted for radium Ra 223.  Subgroup analyses in the randomized controlled trials have concluded that no dose adjustment is needed in patients with mild to moderate renal impairment, and mild hepatic impairment.  No dose adjustment can be recommended for patients with severe renal impairment or moderate to severe hepatic impairment.  Caution is advised if used in these patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (21216, 27191, 'Radium Ra 223 dichloride', 'Liver Failure', 'No dedicated hepatic or renal impairment studies have been conducted for radium Ra 223.  Subgroup analyses in the randomized controlled trials have concluded that no dose adjustment is needed in patients with mild to moderate renal impairment, and mild hepatic impairment.  No dose adjustment can be recommended for patients with severe renal impairment or moderate to severe hepatic impairment.  Caution is advised if used in these patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (21217, 27192, 'Radium Ra 223 dichloride', 'Liver Failure', 'No dedicated hepatic or renal impairment studies have been conducted for radium Ra 223.  Subgroup analyses in the randomized controlled trials have concluded that no dose adjustment is needed in patients with mild to moderate renal impairment, and mild hepatic impairment.  No dose adjustment can be recommended for patients with severe renal impairment or moderate to severe hepatic impairment.  Caution is advised if used in these patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (21218, 27196, 'Radium Ra 223 dichloride', 'Liver Failure', 'No dedicated hepatic or renal impairment studies have been conducted for radium Ra 223.  Subgroup analyses in the randomized controlled trials have concluded that no dose adjustment is needed in patients with mild to moderate renal impairment, and mild hepatic impairment.  No dose adjustment can be recommended for patients with severe renal impairment or moderate to severe hepatic impairment.  Caution is advised if used in these patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (21219, 27197, 'Radium Ra 223 dichloride', 'Liver Failure', 'No dedicated hepatic or renal impairment studies have been conducted for radium Ra 223.  Subgroup analyses in the randomized controlled trials have concluded that no dose adjustment is needed in patients with mild to moderate renal impairment, and mild hepatic impairment.  No dose adjustment can be recommended for patients with severe renal impairment or moderate to severe hepatic impairment.  Caution is advised if used in these patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (21220, 27198, 'Radium Ra 223 dichloride', 'Liver Failure', 'No dedicated hepatic or renal impairment studies have been conducted for radium Ra 223.  Subgroup analyses in the randomized controlled trials have concluded that no dose adjustment is needed in patients with mild to moderate renal impairment, and mild hepatic impairment.  No dose adjustment can be recommended for patients with severe renal impairment or moderate to severe hepatic impairment.  Caution is advised if used in these patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (21221, 27199, 'Radium Ra 223 dichloride', 'Liver Failure', 'No dedicated hepatic or renal impairment studies have been conducted for radium Ra 223.  Subgroup analyses in the randomized controlled trials have concluded that no dose adjustment is needed in patients with mild to moderate renal impairment, and mild hepatic impairment.  No dose adjustment can be recommended for patients with severe renal impairment or moderate to severe hepatic impairment.  Caution is advised if used in these patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (21222, 27200, 'Radium Ra 223 dichloride', 'Liver Failure', 'No dedicated hepatic or renal impairment studies have been conducted for radium Ra 223.  Subgroup analyses in the randomized controlled trials have concluded that no dose adjustment is needed in patients with mild to moderate renal impairment, and mild hepatic impairment.  No dose adjustment can be recommended for patients with severe renal impairment or moderate to severe hepatic impairment.  Caution is advised if used in these patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (21223, 27201, 'Radium Ra 223 dichloride', 'Liver Failure', 'No dedicated hepatic or renal impairment studies have been conducted for radium Ra 223.  Subgroup analyses in the randomized controlled trials have concluded that no dose adjustment is needed in patients with mild to moderate renal impairment, and mild hepatic impairment.  No dose adjustment can be recommended for patients with severe renal impairment or moderate to severe hepatic impairment.  Caution is advised if used in these patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (21224, 27202, 'Radium Ra 223 dichloride', 'Liver Failure', 'No dedicated hepatic or renal impairment studies have been conducted for radium Ra 223.  Subgroup analyses in the randomized controlled trials have concluded that no dose adjustment is needed in patients with mild to moderate renal impairment, and mild hepatic impairment.  No dose adjustment can be recommended for patients with severe renal impairment or moderate to severe hepatic impairment.  Caution is advised if used in these patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (21225, 27204, 'Radium Ra 223 dichloride', 'Liver Failure', 'No dedicated hepatic or renal impairment studies have been conducted for radium Ra 223.  Subgroup analyses in the randomized controlled trials have concluded that no dose adjustment is needed in patients with mild to moderate renal impairment, and mild hepatic impairment.  No dose adjustment can be recommended for patients with severe renal impairment or moderate to severe hepatic impairment.  Caution is advised if used in these patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (21226, 27205, 'Radium Ra 223 dichloride', 'Liver Failure', 'No dedicated hepatic or renal impairment studies have been conducted for radium Ra 223.  Subgroup analyses in the randomized controlled trials have concluded that no dose adjustment is needed in patients with mild to moderate renal impairment, and mild hepatic impairment.  No dose adjustment can be recommended for patients with severe renal impairment or moderate to severe hepatic impairment.  Caution is advised if used in these patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (21227, 27206, 'Radium Ra 223 dichloride', 'Liver Failure', 'No dedicated hepatic or renal impairment studies have been conducted for radium Ra 223.  Subgroup analyses in the randomized controlled trials have concluded that no dose adjustment is needed in patients with mild to moderate renal impairment, and mild hepatic impairment.  No dose adjustment can be recommended for patients with severe renal impairment or moderate to severe hepatic impairment.  Caution is advised if used in these patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (21228, 27207, 'Radium Ra 223 dichloride', 'Liver Failure', 'No dedicated hepatic or renal impairment studies have been conducted for radium Ra 223.  Subgroup analyses in the randomized controlled trials have concluded that no dose adjustment is needed in patients with mild to moderate renal impairment, and mild hepatic impairment.  No dose adjustment can be recommended for patients with severe renal impairment or moderate to severe hepatic impairment.  Caution is advised if used in these patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (21229, 32245, 'Radium Ra 223 dichloride', 'Liver Failure', 'No dedicated hepatic or renal impairment studies have been conducted for radium Ra 223.  Subgroup analyses in the randomized controlled trials have concluded that no dose adjustment is needed in patients with mild to moderate renal impairment, and mild hepatic impairment.  No dose adjustment can be recommended for patients with severe renal impairment or moderate to severe hepatic impairment.  Caution is advised if used in these patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (21230, 25553, 'Quinidine', 'Cardiomyopathies', 'Antiarrhythmic agents can induce severe hypotension (particularly with IV administration) or induce or worsen congestive heart failure (CHF).  Patients with primary cardiomyopathy or inadequately compensated CHF are at increased risk.  Antiarrhythmic agents should be administered cautiously and dosage and/or frequency of administration modified in patients with hypotension or adequately compensated CHF.  Alternative therapy should be considered unless these conditions are secondary to cardiac arrhythmia.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (21231, 25553, 'Quinidine', 'Arrhythmias, Cardiac', 'Antiarrhythmic agents can induce or worsen ventricular arrhythmias.  Ventricular tachycardia, ventricular fibrillation, and torsades de pointes have occurred in some patients.  Patients with underlying cardiac dysfunction, bradycardia, hypokalemia, hypomagnesemia, or high antiarrhythmic serum concentrations are at increased risk for drug-induced arrhythmias.  Therapy with antiarrhythmics should be used with extreme caution in patients with or predisposed to arrhythmias.  Evidence of improved survival is lacking for use of antiarrhythmic therapy in asymptomatic, non-life-threatening arrhythmias.  Therapy with antiarrhythmic agents should be reserved for patients with life-threatening arrhythmias.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (21232, 25553, 'Quinidine', 'Anticholinergic Syndrome', 'The use of quinidine is contraindicated in patients with preexisting conditions that are likely to be exacerbated by anticholinergic activity, such as myasthenia gravis, glaucoma, and urinary retention or obstruction.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (21233, 25553, 'Quinidine', 'Sick Sinus Syndrome', 'The use of quinidine is contraindicated for use in patients without a functioning artificial pacemaker whose cardiac rhythm is dependent upon a junctional or idioventricular pacemaker, including patients with complete AV block.  Therapy with quinidine should be administered with caution in patients with severe sinus-node dysfunction such as sick sinus syndrome, bradycardia-tachycardia syndrome, or second- or third-degree heart block.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (21234, 25553, 'Quinidine', 'Water-Electrolyte Imbalance', 'Electrolyte imbalance can alter the therapeutic effectiveness of antiarrhythmic agents.  Hypokalemia and hypomagnesemia can reduce the effectiveness of antiarrhythmic agents.  In some cases, these disorders can exaggerate the degree of QTc prolongation and increase the potential for torsade de pointes.  Hyperkalemia can potentiate the toxic effects of antiarrhythmic agents.  Electrolyte imbalance should be corrected prior to initiating antiarrhythmic therapy.  Clinical monitoring of cardiac function and electrolyte concentrations is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (21235, 25553, 'Quinidine', 'Liver Diseases', 'Quinidine is primarily metabolized by the liver to active and inactive forms.  Hepatic dysfunction causes a slowed metabolism and elimination of the drug which can lead to quinidine toxicity if dosage is not appropriately reduced.  Clinical monitoring of hepatic function is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (21236, 25553, 'Quinidine', 'Kidney Diseases', 'Renal dysfunction causes a slowed elimination of quinidine which can lead to quinidine toxicity if dosage is not appropriately reduced.  Therapy with quinidine should be administered cautiously and dosages reduced in patients with compromised renal function.  Quinidine is not appreciably removed by hemodialysis.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (21237, 9420, 'Raloxifene', 'Thromboembolism', 'The use of raloxifene is contraindicated in patients with active or past history of venous thromboembolic events, including deep vein thrombosis, pulmonary embolism, and retinal vein thrombosis.  In clinical trials, women treated with raloxifene had an increased risk of venous thromboembolism.  A less serious event, superficial thrombophlebitis, also has been reported more frequently with raloxifene.  The greatest risk for deep vein thrombosis and pulmonary embolism occurs during the first four months of treatment.  Therapy with raloxifene should be considered cautiously in women at risk for thromboembolic disease for other reasons, such as congestive heart failure, superficial thrombophlebitis, and active malignancy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (21238, 17146, 'Raloxifene', 'Thromboembolism', 'The use of raloxifene is contraindicated in patients with active or past history of venous thromboembolic events, including deep vein thrombosis, pulmonary embolism, and retinal vein thrombosis.  In clinical trials, women treated with raloxifene had an increased risk of venous thromboembolism.  A less serious event, superficial thrombophlebitis, also has been reported more frequently with raloxifene.  The greatest risk for deep vein thrombosis and pulmonary embolism occurs during the first four months of treatment.  Therapy with raloxifene should be considered cautiously in women at risk for thromboembolic disease for other reasons, such as congestive heart failure, superficial thrombophlebitis, and active malignancy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (21239, 9420, 'Raloxifene', 'Heart Diseases', 'In studies of postmenopausal women with documented coronary heart disease or at increased risk for coronary events, an increased risk of death due to stroke was observed after treatment with raloxifene.  The risk-benefit balance should be considered in women at risk for stroke, such as prior stroke or transient ischemic attack (TIA), atrial fibrillation, hypertension, or cigarette smoking.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (21240, 17146, 'Raloxifene', 'Heart Diseases', 'In studies of postmenopausal women with documented coronary heart disease or at increased risk for coronary events, an increased risk of death due to stroke was observed after treatment with raloxifene.  The risk-benefit balance should be considered in women at risk for stroke, such as prior stroke or transient ischemic attack (TIA), atrial fibrillation, hypertension, or cigarette smoking.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (21241, 9420, 'Raloxifene', 'Hypertriglyceridemia', 'In studies of women with a history of marked hypertriglyceridemia (>5.6 mmol/L or >500 mg/dL) in response to treatment with oral estrogen or estrogen plus progestin may develop increased levels of triglycerides when treated with raloxifene.  Women with this medical history should have serum triglycerides monitored when taking raloxifene.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (21242, 17146, 'Raloxifene', 'Hypertriglyceridemia', 'In studies of women with a history of marked hypertriglyceridemia (>5.6 mmol/L or >500 mg/dL) in response to treatment with oral estrogen or estrogen plus progestin may develop increased levels of triglycerides when treated with raloxifene.  Women with this medical history should have serum triglycerides monitored when taking raloxifene.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (21243, 9420, 'Raloxifene', 'Liver Diseases', 'Raloxifene undergoes extensive first-pass metabolism in the liver.  Following administration of a single oral dose in Child-Pugh Class A patients with cirrhosis and total serum bilirubin ranging from 0.6 to 2.0 mg/dL, plasma raloxifene concentrations were 2.5 times higher than in controls.  Therapy with raloxifene should be administered cautiously in patients with hepatic insufficiency, since safety and efficacy have not been evaluated.  Although raloxifene is generally well tolerated, even at dosages higher than currently recommended, patients with liver disease should be monitored for occurrence of undue adverse effects during raloxifene therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (21244, 17146, 'Raloxifene', 'Liver Diseases', 'Raloxifene undergoes extensive first-pass metabolism in the liver.  Following administration of a single oral dose in Child-Pugh Class A patients with cirrhosis and total serum bilirubin ranging from 0.6 to 2.0 mg/dL, plasma raloxifene concentrations were 2.5 times higher than in controls.  Therapy with raloxifene should be administered cautiously in patients with hepatic insufficiency, since safety and efficacy have not been evaluated.  Although raloxifene is generally well tolerated, even at dosages higher than currently recommended, patients with liver disease should be monitored for occurrence of undue adverse effects during raloxifene therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (21245, 9420, 'Raloxifene', 'Kidney Diseases', 'Raloxifene should be used with caution in patients with moderate or severe renal impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (21246, 17146, 'Raloxifene', 'Kidney Diseases', 'Raloxifene should be used with caution in patients with moderate or severe renal impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (21247, 27447, 'Azilsartan medoxomil', 'Diabetes Mellitus', 'The coadministration of some angiotensin II receptor blocker agents with aliskiren is contraindicated in patients with diabetes.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (21248, 27448, 'Azilsartan medoxomil', 'Diabetes Mellitus', 'The coadministration of some angiotensin II receptor blocker agents with aliskiren is contraindicated in patients with diabetes.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (21249, 27447, 'Azilsartan medoxomil', 'Angioedema', 'The use of these agents is contraindicated in patients with a history of angioedema related to previous angiotensin-converting enzyme (ACE) inhibitor or angiotensin II receptor blocker (ARB) therapy or in patients with hereditary angioedema.  Patients with a history of angioedema unrelated to these agents may be at increased risk of angioedema while receiving angiotensin II receptor (AR) antagonists.  Patients should be advised to immediately report any signs or symptoms suggestive of angioedema (swelling of face, extremities, eyes, lips, or tongue, or difficulty swallowing or breathing) and to stop taking the medication until otherwise directed by their physician.  Emergency therapy and/or measures to prevent airway obstruction are required for angioedema involving the tongue, glottis, or larynx.  Treatment with angiotensin II receptor (AR) antagonists should be discontinued permanently if angioedema develops in association with therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (21250, 27448, 'Azilsartan medoxomil', 'Angioedema', 'The use of these agents is contraindicated in patients with a history of angioedema related to previous angiotensin-converting enzyme (ACE) inhibitor or angiotensin II receptor blocker (ARB) therapy or in patients with hereditary angioedema.  Patients with a history of angioedema unrelated to these agents may be at increased risk of angioedema while receiving angiotensin II receptor (AR) antagonists.  Patients should be advised to immediately report any signs or symptoms suggestive of angioedema (swelling of face, extremities, eyes, lips, or tongue, or difficulty swallowing or breathing) and to stop taking the medication until otherwise directed by their physician.  Emergency therapy and/or measures to prevent airway obstruction are required for angioedema involving the tongue, glottis, or larynx.  Treatment with angiotensin II receptor (AR) antagonists should be discontinued permanently if angioedema develops in association with therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (21251, 27447, 'Azilsartan medoxomil', 'Hypotension', 'Angiotensin II receptor (AR) antagonists can cause symptomatic hypotension in patients with an activated renin-angiotensin system, such as volume- and/or sodium-depleted patients.  Therapy with AR antagonists should be administered cautiously in such patients and in those predisposed to hypovolemic or hyponatremic states (e.g., patients on diuretic therapy, especially if high doses were used or if recently instituted; those on dietary salt restriction; renal dialysis patients).  Volume and/or sodium depletion should be corrected prior to initiating therapy with AR antagonists, and the patient should be hemodynamically stable.  Ideally, patients at risk for excessive hypotension should initiate AR antagonist therapy under close medical supervision, preferably with a lower dose, and followed closely for the first 2 weeks of treatment and whenever the dosage of AR antagonist or diuretic is increased.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (21252, 27448, 'Azilsartan medoxomil', 'Hypotension', 'Angiotensin II receptor (AR) antagonists can cause symptomatic hypotension in patients with an activated renin-angiotensin system, such as volume- and/or sodium-depleted patients.  Therapy with AR antagonists should be administered cautiously in such patients and in those predisposed to hypovolemic or hyponatremic states (e.g., patients on diuretic therapy, especially if high doses were used or if recently instituted; those on dietary salt restriction; renal dialysis patients).  Volume and/or sodium depletion should be corrected prior to initiating therapy with AR antagonists, and the patient should be hemodynamically stable.  Ideally, patients at risk for excessive hypotension should initiate AR antagonist therapy under close medical supervision, preferably with a lower dose, and followed closely for the first 2 weeks of treatment and whenever the dosage of AR antagonist or diuretic is increased.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (21253, 27447, 'Azilsartan medoxomil', 'Heart Failure', 'Angiotensin II receptor (AR) antagonists can cause renal impairment in patients whose renal function depends on the activity of the renin-angiotensin-aldosterone system.  In addition, symptomatic hypotension can occur in susceptible individuals, which may compromise renal and myocardial perfusion.  In patients with severe congestive heart failure (CHF), treatment with AR antagonists has been associated with oliguria and/or progressive azotemia and, rarely, renal failure, myocardial ischemia, and death.  Therapy with AR antagonists should be initiated cautiously in patients with severe CHF, especially when accompanied by volume and/or sodium depletion.  In patients who experience a decline in renal function, discontinuation of AR antagonist therapy is usually not required provided there is symptomatic improvement of the heart failure and renal deterioration is well-tolerated.  Transient hypotension is also not a contraindication to further treatment with AR antagonists, since therapy can usually be reinstated without difficulty after blood pressure stabilizes.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (21254, 27448, 'Azilsartan medoxomil', 'Heart Failure', 'Angiotensin II receptor (AR) antagonists can cause renal impairment in patients whose renal function depends on the activity of the renin-angiotensin-aldosterone system.  In addition, symptomatic hypotension can occur in susceptible individuals, which may compromise renal and myocardial perfusion.  In patients with severe congestive heart failure (CHF), treatment with AR antagonists has been associated with oliguria and/or progressive azotemia and, rarely, renal failure, myocardial ischemia, and death.  Therapy with AR antagonists should be initiated cautiously in patients with severe CHF, especially when accompanied by volume and/or sodium depletion.  In patients who experience a decline in renal function, discontinuation of AR antagonist therapy is usually not required provided there is symptomatic improvement of the heart failure and renal deterioration is well-tolerated.  Transient hypotension is also not a contraindication to further treatment with AR antagonists, since therapy can usually be reinstated without difficulty after blood pressure stabilizes.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (21255, 27447, 'Azilsartan medoxomil', 'Hyperkalemia', 'Drugs that inhibit the renin-angiotensin, such as angiotensin II receptor antagonist system can cause hyperkalemia.  Concomitant use of these agents with drugs that increase potassium levels may increase the risk of hyperkalemia.  Use caution when using these agents together and monitor serum potassium periodically.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (21256, 27448, 'Azilsartan medoxomil', 'Hyperkalemia', 'Drugs that inhibit the renin-angiotensin, such as angiotensin II receptor antagonist system can cause hyperkalemia.  Concomitant use of these agents with drugs that increase potassium levels may increase the risk of hyperkalemia.  Use caution when using these agents together and monitor serum potassium periodically.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (21257, 27447, 'Azilsartan medoxomil', 'Renal Artery Obstruction', 'In patients with bilateral renal artery stenosis or renal artery stenosis in a solitary kidney, angiotensin II receptor (AR) antagonists may reduce renal perfusion to a critically low level.  Increases in serum creatinine or blood urea nitrogen have been reported with ACE inhibitors, a class of drugs that also block the renin-angiotensin-aldosterone system.  Although there are no long-term data on the use of AR antagonists in patients with renal artery stenosis, a similar effect should be anticipated.  Renal function should be monitored closely for the first few weeks of therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (21258, 27448, 'Azilsartan medoxomil', 'Renal Artery Obstruction', 'In patients with bilateral renal artery stenosis or renal artery stenosis in a solitary kidney, angiotensin II receptor (AR) antagonists may reduce renal perfusion to a critically low level.  Increases in serum creatinine or blood urea nitrogen have been reported with ACE inhibitors, a class of drugs that also block the renin-angiotensin-aldosterone system.  Although there are no long-term data on the use of AR antagonists in patients with renal artery stenosis, a similar effect should be anticipated.  Renal function should be monitored closely for the first few weeks of therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (21259, 27447, 'Azilsartan medoxomil', 'Kidney Diseases', 'Changes in renal function including acute renal failure can be caused by drugs that inhibit the renin-angiotensin system and by diuretics.  Patients whose renal function may depend in part on the activity of the renin-angiotensin system (e.g., patients with renal artery stenosis, chronic kidney disease, severe congestive heart failure, or volume depletion) may be at particular risk of developing acute renal failure with these agents.  Monitor renal function periodically in these patients.  Consider withholding or discontinuing therapy in patients who develop a clinically significant decrease in renal function with these agents.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (21260, 27448, 'Azilsartan medoxomil', 'Kidney Diseases', 'Changes in renal function including acute renal failure can be caused by drugs that inhibit the renin-angiotensin system and by diuretics.  Patients whose renal function may depend in part on the activity of the renin-angiotensin system (e.g., patients with renal artery stenosis, chronic kidney disease, severe congestive heart failure, or volume depletion) may be at particular risk of developing acute renal failure with these agents.  Monitor renal function periodically in these patients.  Consider withholding or discontinuing therapy in patients who develop a clinically significant decrease in renal function with these agents.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (21261, 27447, 'Azilsartan medoxomil', 'Liver Diseases', 'No dose adjustment of azilsartan is necessary in patients with mild or moderate hepatic impairment.  Azilsartan has not been studied in patients with severe hepatic impairment and caution should be exercised if used in these patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (21262, 27448, 'Azilsartan medoxomil', 'Liver Diseases', 'No dose adjustment of azilsartan is necessary in patients with mild or moderate hepatic impairment.  Azilsartan has not been studied in patients with severe hepatic impairment and caution should be exercised if used in these patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (21263, 0, 'Pyrantel', 'Liver Diseases', 'The use of pyrantel is contraindicated in patients with liver disease.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (21264, 1411, 'Rabeprazole', 'Clostridium Infections', 'Published observational studies suggest that proton pump inhibitor (PPI) use may be associated with an increased risk of Clostridium difficile-associated diarrhea (CDAD), especially in hospitalized patients.  This diagnosis should be considered for diarrhea that does not improve.  It is recommended that patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.  Close monitoring is recommended in patients with diarrhea and in those taking antibacterial agents as CDAD has been reported with the use of nearly all these agents.  Treatment with antibacterial agents alters the normal flora of the colon, leading to overgrowth of C.  difficile.  C.  difficile produces toxins A and B, which contribute to the development of CDAD.  Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C.  difficile, and surgical evaluation should be instituted as clinically indicated.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (21265, 8486, 'Rabeprazole', 'Clostridium Infections', 'Published observational studies suggest that proton pump inhibitor (PPI) use may be associated with an increased risk of Clostridium difficile-associated diarrhea (CDAD), especially in hospitalized patients.  This diagnosis should be considered for diarrhea that does not improve.  It is recommended that patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.  Close monitoring is recommended in patients with diarrhea and in those taking antibacterial agents as CDAD has been reported with the use of nearly all these agents.  Treatment with antibacterial agents alters the normal flora of the colon, leading to overgrowth of C.  difficile.  C.  difficile produces toxins A and B, which contribute to the development of CDAD.  Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C.  difficile, and surgical evaluation should be instituted as clinically indicated.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (21266, 12963, 'Rabeprazole', 'Clostridium Infections', 'Published observational studies suggest that proton pump inhibitor (PPI) use may be associated with an increased risk of Clostridium difficile-associated diarrhea (CDAD), especially in hospitalized patients.  This diagnosis should be considered for diarrhea that does not improve.  It is recommended that patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.  Close monitoring is recommended in patients with diarrhea and in those taking antibacterial agents as CDAD has been reported with the use of nearly all these agents.  Treatment with antibacterial agents alters the normal flora of the colon, leading to overgrowth of C.  difficile.  C.  difficile produces toxins A and B, which contribute to the development of CDAD.  Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C.  difficile, and surgical evaluation should be instituted as clinically indicated.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (21267, 12969, 'Rabeprazole', 'Clostridium Infections', 'Published observational studies suggest that proton pump inhibitor (PPI) use may be associated with an increased risk of Clostridium difficile-associated diarrhea (CDAD), especially in hospitalized patients.  This diagnosis should be considered for diarrhea that does not improve.  It is recommended that patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.  Close monitoring is recommended in patients with diarrhea and in those taking antibacterial agents as CDAD has been reported with the use of nearly all these agents.  Treatment with antibacterial agents alters the normal flora of the colon, leading to overgrowth of C.  difficile.  C.  difficile produces toxins A and B, which contribute to the development of CDAD.  Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C.  difficile, and surgical evaluation should be instituted as clinically indicated.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (21268, 12970, 'Rabeprazole', 'Clostridium Infections', 'Published observational studies suggest that proton pump inhibitor (PPI) use may be associated with an increased risk of Clostridium difficile-associated diarrhea (CDAD), especially in hospitalized patients.  This diagnosis should be considered for diarrhea that does not improve.  It is recommended that patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.  Close monitoring is recommended in patients with diarrhea and in those taking antibacterial agents as CDAD has been reported with the use of nearly all these agents.  Treatment with antibacterial agents alters the normal flora of the colon, leading to overgrowth of C.  difficile.  C.  difficile produces toxins A and B, which contribute to the development of CDAD.  Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C.  difficile, and surgical evaluation should be instituted as clinically indicated.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (21269, 13021, 'Rabeprazole', 'Clostridium Infections', 'Published observational studies suggest that proton pump inhibitor (PPI) use may be associated with an increased risk of Clostridium difficile-associated diarrhea (CDAD), especially in hospitalized patients.  This diagnosis should be considered for diarrhea that does not improve.  It is recommended that patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.  Close monitoring is recommended in patients with diarrhea and in those taking antibacterial agents as CDAD has been reported with the use of nearly all these agents.  Treatment with antibacterial agents alters the normal flora of the colon, leading to overgrowth of C.  difficile.  C.  difficile produces toxins A and B, which contribute to the development of CDAD.  Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C.  difficile, and surgical evaluation should be instituted as clinically indicated.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (21270, 13025, 'Rabeprazole', 'Clostridium Infections', 'Published observational studies suggest that proton pump inhibitor (PPI) use may be associated with an increased risk of Clostridium difficile-associated diarrhea (CDAD), especially in hospitalized patients.  This diagnosis should be considered for diarrhea that does not improve.  It is recommended that patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.  Close monitoring is recommended in patients with diarrhea and in those taking antibacterial agents as CDAD has been reported with the use of nearly all these agents.  Treatment with antibacterial agents alters the normal flora of the colon, leading to overgrowth of C.  difficile.  C.  difficile produces toxins A and B, which contribute to the development of CDAD.  Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C.  difficile, and surgical evaluation should be instituted as clinically indicated.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (21271, 13027, 'Rabeprazole', 'Clostridium Infections', 'Published observational studies suggest that proton pump inhibitor (PPI) use may be associated with an increased risk of Clostridium difficile-associated diarrhea (CDAD), especially in hospitalized patients.  This diagnosis should be considered for diarrhea that does not improve.  It is recommended that patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.  Close monitoring is recommended in patients with diarrhea and in those taking antibacterial agents as CDAD has been reported with the use of nearly all these agents.  Treatment with antibacterial agents alters the normal flora of the colon, leading to overgrowth of C.  difficile.  C.  difficile produces toxins A and B, which contribute to the development of CDAD.  Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C.  difficile, and surgical evaluation should be instituted as clinically indicated.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (21272, 15087, 'Rabeprazole', 'Clostridium Infections', 'Published observational studies suggest that proton pump inhibitor (PPI) use may be associated with an increased risk of Clostridium difficile-associated diarrhea (CDAD), especially in hospitalized patients.  This diagnosis should be considered for diarrhea that does not improve.  It is recommended that patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.  Close monitoring is recommended in patients with diarrhea and in those taking antibacterial agents as CDAD has been reported with the use of nearly all these agents.  Treatment with antibacterial agents alters the normal flora of the colon, leading to overgrowth of C.  difficile.  C.  difficile produces toxins A and B, which contribute to the development of CDAD.  Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C.  difficile, and surgical evaluation should be instituted as clinically indicated.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (21273, 20623, 'Rabeprazole', 'Clostridium Infections', 'Published observational studies suggest that proton pump inhibitor (PPI) use may be associated with an increased risk of Clostridium difficile-associated diarrhea (CDAD), especially in hospitalized patients.  This diagnosis should be considered for diarrhea that does not improve.  It is recommended that patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.  Close monitoring is recommended in patients with diarrhea and in those taking antibacterial agents as CDAD has been reported with the use of nearly all these agents.  Treatment with antibacterial agents alters the normal flora of the colon, leading to overgrowth of C.  difficile.  C.  difficile produces toxins A and B, which contribute to the development of CDAD.  Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C.  difficile, and surgical evaluation should be instituted as clinically indicated.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (21274, 20713, 'Rabeprazole', 'Clostridium Infections', 'Published observational studies suggest that proton pump inhibitor (PPI) use may be associated with an increased risk of Clostridium difficile-associated diarrhea (CDAD), especially in hospitalized patients.  This diagnosis should be considered for diarrhea that does not improve.  It is recommended that patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.  Close monitoring is recommended in patients with diarrhea and in those taking antibacterial agents as CDAD has been reported with the use of nearly all these agents.  Treatment with antibacterial agents alters the normal flora of the colon, leading to overgrowth of C.  difficile.  C.  difficile produces toxins A and B, which contribute to the development of CDAD.  Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C.  difficile, and surgical evaluation should be instituted as clinically indicated.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (21275, 24449, 'Rabeprazole', 'Clostridium Infections', 'Published observational studies suggest that proton pump inhibitor (PPI) use may be associated with an increased risk of Clostridium difficile-associated diarrhea (CDAD), especially in hospitalized patients.  This diagnosis should be considered for diarrhea that does not improve.  It is recommended that patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.  Close monitoring is recommended in patients with diarrhea and in those taking antibacterial agents as CDAD has been reported with the use of nearly all these agents.  Treatment with antibacterial agents alters the normal flora of the colon, leading to overgrowth of C.  difficile.  C.  difficile produces toxins A and B, which contribute to the development of CDAD.  Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C.  difficile, and surgical evaluation should be instituted as clinically indicated.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (21276, 24576, 'Rabeprazole', 'Clostridium Infections', 'Published observational studies suggest that proton pump inhibitor (PPI) use may be associated with an increased risk of Clostridium difficile-associated diarrhea (CDAD), especially in hospitalized patients.  This diagnosis should be considered for diarrhea that does not improve.  It is recommended that patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.  Close monitoring is recommended in patients with diarrhea and in those taking antibacterial agents as CDAD has been reported with the use of nearly all these agents.  Treatment with antibacterial agents alters the normal flora of the colon, leading to overgrowth of C.  difficile.  C.  difficile produces toxins A and B, which contribute to the development of CDAD.  Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C.  difficile, and surgical evaluation should be instituted as clinically indicated.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (21277, 24577, 'Rabeprazole', 'Clostridium Infections', 'Published observational studies suggest that proton pump inhibitor (PPI) use may be associated with an increased risk of Clostridium difficile-associated diarrhea (CDAD), especially in hospitalized patients.  This diagnosis should be considered for diarrhea that does not improve.  It is recommended that patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.  Close monitoring is recommended in patients with diarrhea and in those taking antibacterial agents as CDAD has been reported with the use of nearly all these agents.  Treatment with antibacterial agents alters the normal flora of the colon, leading to overgrowth of C.  difficile.  C.  difficile produces toxins A and B, which contribute to the development of CDAD.  Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C.  difficile, and surgical evaluation should be instituted as clinically indicated.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (21278, 25607, 'Rabeprazole', 'Clostridium Infections', 'Published observational studies suggest that proton pump inhibitor (PPI) use may be associated with an increased risk of Clostridium difficile-associated diarrhea (CDAD), especially in hospitalized patients.  This diagnosis should be considered for diarrhea that does not improve.  It is recommended that patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.  Close monitoring is recommended in patients with diarrhea and in those taking antibacterial agents as CDAD has been reported with the use of nearly all these agents.  Treatment with antibacterial agents alters the normal flora of the colon, leading to overgrowth of C.  difficile.  C.  difficile produces toxins A and B, which contribute to the development of CDAD.  Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C.  difficile, and surgical evaluation should be instituted as clinically indicated.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (21279, 25608, 'Rabeprazole', 'Clostridium Infections', 'Published observational studies suggest that proton pump inhibitor (PPI) use may be associated with an increased risk of Clostridium difficile-associated diarrhea (CDAD), especially in hospitalized patients.  This diagnosis should be considered for diarrhea that does not improve.  It is recommended that patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.  Close monitoring is recommended in patients with diarrhea and in those taking antibacterial agents as CDAD has been reported with the use of nearly all these agents.  Treatment with antibacterial agents alters the normal flora of the colon, leading to overgrowth of C.  difficile.  C.  difficile produces toxins A and B, which contribute to the development of CDAD.  Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C.  difficile, and surgical evaluation should be instituted as clinically indicated.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (21280, 28647, 'Rabeprazole', 'Clostridium Infections', 'Published observational studies suggest that proton pump inhibitor (PPI) use may be associated with an increased risk of Clostridium difficile-associated diarrhea (CDAD), especially in hospitalized patients.  This diagnosis should be considered for diarrhea that does not improve.  It is recommended that patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.  Close monitoring is recommended in patients with diarrhea and in those taking antibacterial agents as CDAD has been reported with the use of nearly all these agents.  Treatment with antibacterial agents alters the normal flora of the colon, leading to overgrowth of C.  difficile.  C.  difficile produces toxins A and B, which contribute to the development of CDAD.  Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C.  difficile, and surgical evaluation should be instituted as clinically indicated.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (21281, 32205, 'Rabeprazole', 'Clostridium Infections', 'Published observational studies suggest that proton pump inhibitor (PPI) use may be associated with an increased risk of Clostridium difficile-associated diarrhea (CDAD), especially in hospitalized patients.  This diagnosis should be considered for diarrhea that does not improve.  It is recommended that patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.  Close monitoring is recommended in patients with diarrhea and in those taking antibacterial agents as CDAD has been reported with the use of nearly all these agents.  Treatment with antibacterial agents alters the normal flora of the colon, leading to overgrowth of C.  difficile.  C.  difficile produces toxins A and B, which contribute to the development of CDAD.  Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C.  difficile, and surgical evaluation should be instituted as clinically indicated.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (21282, 1411, 'Rabeprazole', 'Fractures, Bone', 'Various published observational studies have reported that PPI therapy may be associated with an increased risk for osteoporosis related fractures of the hip, wrist or spine.  The risk was increased in patients who received high doses (multiple daily doses), and long term treatment (a year or longer).  Patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.  Caution should be used in patients at risk for osteoporosis related fractures and should be managed according to established treatment guidelines.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (21283, 8486, 'Rabeprazole', 'Fractures, Bone', 'Various published observational studies have reported that PPI therapy may be associated with an increased risk for osteoporosis related fractures of the hip, wrist or spine.  The risk was increased in patients who received high doses (multiple daily doses), and long term treatment (a year or longer).  Patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.  Caution should be used in patients at risk for osteoporosis related fractures and should be managed according to established treatment guidelines.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (21284, 12963, 'Rabeprazole', 'Fractures, Bone', 'Various published observational studies have reported that PPI therapy may be associated with an increased risk for osteoporosis related fractures of the hip, wrist or spine.  The risk was increased in patients who received high doses (multiple daily doses), and long term treatment (a year or longer).  Patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.  Caution should be used in patients at risk for osteoporosis related fractures and should be managed according to established treatment guidelines.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (21285, 12969, 'Rabeprazole', 'Fractures, Bone', 'Various published observational studies have reported that PPI therapy may be associated with an increased risk for osteoporosis related fractures of the hip, wrist or spine.  The risk was increased in patients who received high doses (multiple daily doses), and long term treatment (a year or longer).  Patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.  Caution should be used in patients at risk for osteoporosis related fractures and should be managed according to established treatment guidelines.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (21286, 12970, 'Rabeprazole', 'Fractures, Bone', 'Various published observational studies have reported that PPI therapy may be associated with an increased risk for osteoporosis related fractures of the hip, wrist or spine.  The risk was increased in patients who received high doses (multiple daily doses), and long term treatment (a year or longer).  Patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.  Caution should be used in patients at risk for osteoporosis related fractures and should be managed according to established treatment guidelines.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (21287, 13021, 'Rabeprazole', 'Fractures, Bone', 'Various published observational studies have reported that PPI therapy may be associated with an increased risk for osteoporosis related fractures of the hip, wrist or spine.  The risk was increased in patients who received high doses (multiple daily doses), and long term treatment (a year or longer).  Patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.  Caution should be used in patients at risk for osteoporosis related fractures and should be managed according to established treatment guidelines.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (21288, 13025, 'Rabeprazole', 'Fractures, Bone', 'Various published observational studies have reported that PPI therapy may be associated with an increased risk for osteoporosis related fractures of the hip, wrist or spine.  The risk was increased in patients who received high doses (multiple daily doses), and long term treatment (a year or longer).  Patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.  Caution should be used in patients at risk for osteoporosis related fractures and should be managed according to established treatment guidelines.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (21289, 13027, 'Rabeprazole', 'Fractures, Bone', 'Various published observational studies have reported that PPI therapy may be associated with an increased risk for osteoporosis related fractures of the hip, wrist or spine.  The risk was increased in patients who received high doses (multiple daily doses), and long term treatment (a year or longer).  Patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.  Caution should be used in patients at risk for osteoporosis related fractures and should be managed according to established treatment guidelines.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (21290, 15087, 'Rabeprazole', 'Fractures, Bone', 'Various published observational studies have reported that PPI therapy may be associated with an increased risk for osteoporosis related fractures of the hip, wrist or spine.  The risk was increased in patients who received high doses (multiple daily doses), and long term treatment (a year or longer).  Patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.  Caution should be used in patients at risk for osteoporosis related fractures and should be managed according to established treatment guidelines.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (21291, 20623, 'Rabeprazole', 'Fractures, Bone', 'Various published observational studies have reported that PPI therapy may be associated with an increased risk for osteoporosis related fractures of the hip, wrist or spine.  The risk was increased in patients who received high doses (multiple daily doses), and long term treatment (a year or longer).  Patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.  Caution should be used in patients at risk for osteoporosis related fractures and should be managed according to established treatment guidelines.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (21292, 20713, 'Rabeprazole', 'Fractures, Bone', 'Various published observational studies have reported that PPI therapy may be associated with an increased risk for osteoporosis related fractures of the hip, wrist or spine.  The risk was increased in patients who received high doses (multiple daily doses), and long term treatment (a year or longer).  Patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.  Caution should be used in patients at risk for osteoporosis related fractures and should be managed according to established treatment guidelines.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (21293, 24449, 'Rabeprazole', 'Fractures, Bone', 'Various published observational studies have reported that PPI therapy may be associated with an increased risk for osteoporosis related fractures of the hip, wrist or spine.  The risk was increased in patients who received high doses (multiple daily doses), and long term treatment (a year or longer).  Patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.  Caution should be used in patients at risk for osteoporosis related fractures and should be managed according to established treatment guidelines.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (21294, 24576, 'Rabeprazole', 'Fractures, Bone', 'Various published observational studies have reported that PPI therapy may be associated with an increased risk for osteoporosis related fractures of the hip, wrist or spine.  The risk was increased in patients who received high doses (multiple daily doses), and long term treatment (a year or longer).  Patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.  Caution should be used in patients at risk for osteoporosis related fractures and should be managed according to established treatment guidelines.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (21295, 24577, 'Rabeprazole', 'Fractures, Bone', 'Various published observational studies have reported that PPI therapy may be associated with an increased risk for osteoporosis related fractures of the hip, wrist or spine.  The risk was increased in patients who received high doses (multiple daily doses), and long term treatment (a year or longer).  Patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.  Caution should be used in patients at risk for osteoporosis related fractures and should be managed according to established treatment guidelines.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (21296, 25607, 'Rabeprazole', 'Fractures, Bone', 'Various published observational studies have reported that PPI therapy may be associated with an increased risk for osteoporosis related fractures of the hip, wrist or spine.  The risk was increased in patients who received high doses (multiple daily doses), and long term treatment (a year or longer).  Patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.  Caution should be used in patients at risk for osteoporosis related fractures and should be managed according to established treatment guidelines.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (21297, 25608, 'Rabeprazole', 'Fractures, Bone', 'Various published observational studies have reported that PPI therapy may be associated with an increased risk for osteoporosis related fractures of the hip, wrist or spine.  The risk was increased in patients who received high doses (multiple daily doses), and long term treatment (a year or longer).  Patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.  Caution should be used in patients at risk for osteoporosis related fractures and should be managed according to established treatment guidelines.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (21298, 28647, 'Rabeprazole', 'Fractures, Bone', 'Various published observational studies have reported that PPI therapy may be associated with an increased risk for osteoporosis related fractures of the hip, wrist or spine.  The risk was increased in patients who received high doses (multiple daily doses), and long term treatment (a year or longer).  Patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.  Caution should be used in patients at risk for osteoporosis related fractures and should be managed according to established treatment guidelines.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (21299, 32205, 'Rabeprazole', 'Fractures, Bone', 'Various published observational studies have reported that PPI therapy may be associated with an increased risk for osteoporosis related fractures of the hip, wrist or spine.  The risk was increased in patients who received high doses (multiple daily doses), and long term treatment (a year or longer).  Patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.  Caution should be used in patients at risk for osteoporosis related fractures and should be managed according to established treatment guidelines.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (21300, 1411, 'Rabeprazole', 'Hypomagnesemia 1, Intestinal', 'Symptomatic and asymptomatic hypomagnesemia has been reported rarely in patients treated with PPIs for at least 3 months, in most cases after a year of therapy.  Serious adverse events can include tetany, seizures, and arrhythmias.  Caution should be used in patients prone to magnesium imbalances such as patients taking other medications that can cause hypomagnesemia (e.g., diuretics).  Regular monitoring is recommended.', '2', '', 'DDInter', 0);
